Therefore, optimizing therapeutic windows for NF‐κB inhibitors and copper chelators/cuproptosis inducers to achieve greater efficacy and fewer side effects will provide a promising strategy for chronic inflammation‐induced cancers (Figure 8). The gene discussed is NFKB1; the disease is cancer.